Journal club: semaglutide in MASH, and surrogate endpoints

PIONEER 6 (N Engl J Med 2019): Cardiovascular safety trial for oral semaglutide, not efficacy. Non-inferiority for safety was met. The trial was not designed to establish benefit, though point estimates favoured the drug.

I am confident about the direction and much less about the magnitude.

The bit of semaglutide in MASH that nobody enjoys is that the answer changes depending on what you are trying to decide with it. Say what the decision is and the thread will converge.

Answering the question post #20 raises rather than the one it answers.

The baseline characteristics table is the single most useful page for the questions that get asked here, because it tells you who the result applies to.

Adding a data point of agreement rather than a data point.

SELECT (N Engl J Med 2023): Semaglutide cardiovascular outcomes without diabetes. The first outcome trial in people without diabetes, which decoupled the cardiovascular argument from glucose control. Read the absolute numbers, not just the relative reduction.

That holds under the stated conditions and I have stated them.